^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ELTD1 expression

    i
    Other names: ELTD1, Adhesion G Protein-Coupled Receptor L4, EGF, Latrophilin And Seven Transmembrane Domain-Containing Protein 1, EGF, Latrophilin And Seven Transmembrane Domain Containing 1, EGF-TM7-Latrophilin-Related Protein, Lnc-ADGRL4-2, ETL Protein, KPG_003
    Entrez ID:
    64123
    almost2years
    ELTD1 Review: New Regulator of Angiogenesis in Glioma. (PubMed, Curr Health Sci J)
    This review aimed to translate these insights into effective clinical treatments. However, several gaps remain in our knowledge regarding ELTD1 ligands and their potential involvement in other physiological or pathological processes that future research can address to elucidate the role of ELTD1 in cancer, through angiogenesis and other intracellular pathways.
    Review • Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    ELTD1 expression
    2years
    Tanshinone IIA normalized hepatocellular carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1. (PubMed, Phytomedicine)
    This study reveals a new mechanism between TSA and ELTD1 for vascular normalization, suggesting that therapeutic or pharmacological intervention with ELTD1 may enhance the efficacy of PD-1 inhibitors in HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    JAK2 (Janus kinase 2) • JAK1 (Janus Kinase 1) • ELTD1 (Adhesion G Protein-Coupled Receptor L4) • TJP1 (Tight Junction Protein 1) • CLDN5 (Claudin 5)
    |
    ELTD1 expression
    over4years
    ELTD1 Promotes Gastric Cancer Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition Through MAPK/ERK Signaling by Regulating CSK. (PubMed, Int J Gen Med)
    Data from TGCA and GEO both revealed that GC patients with high ELTD1 expression had poorer prognosis and the combination of ELTD1 with CSK showed better predictive performance. ELTD1 plays an oncogene role in GC through MAPK/ERK signaling via inhibiting CSK, which may be a useful prognostic predictor and potential therapeutic target for GC.
    Journal
    |
    EGF (Epidermal growth factor) • CSK (C-Terminal Src Kinase) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    ELTD1 expression
    over4years
    ELTD1 promotes invasion and metastasis by activating MMP2 in colorectal cancer. (PubMed, Int J Biol Sci)
    Moreover, ELTD1 accelerated the transcriptional activity of MMP2, which could rescue the impaired invasiveness of CRC cells caused by the downregulation of ELTD1 expression. In conclusion, our study suggests that ELTD1 might be a potential novel target for the treatment of CRC metastasis.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • EGF (Epidermal growth factor) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    ELTD1 expression
    over4years
    ADGRL4/ELTD1 expression in breast cancer cells induces vascular normalisation and immune suppression. (PubMed, Mol Cancer Res)
    Implications: ELTD1 expression in breast tumour xenografts creates an immunosuppressive microenvironment and increases vessel size and perfusion. Its expression may enhance the delivery of therapies targeting the immune system.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    PD-L1 expression • ELTD1 expression
    over4years
    ELTD1-deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma. (PubMed, Neuro Oncol)
    Our data demonstrate that ELTD1 participates in inducing vascular dysfunction in glioma, and suggests that targeting of ELTD1 may normalize the vessels and improve the response to immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    ELTD1 expression
    5years
    ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model. (PubMed, Mult Scler Relat Disord)
    In addition, we found that the blood-brain barrier (BBB) was compromised in the brains of EAE mice using contrast-enhanced MRI (CE-MRI), as well as altered relative cerebral blood flow (rCBF) in the brains and cervical spinal cords of these mice using perfusion imaging, compared to controls. These findings indicate that ELTD1 may be a promising biomarker for CNS-inflammation in MS.
    Journal
    |
    EGF (Epidermal growth factor) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    ELTD1 expression
    5years
    Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib. (PubMed, BMC Cancer)
    Our results identify tumor vessel ELTD1 expression as a positive predictive marker for sunitinib-treatment in patients suffering from mRCC. The negative results in the sorafenib treated group supports ELTD1 being a pure predictive and not a prognostic marker for sunitinib therapy.
    Clinical • Journal
    |
    KDR (Kinase insert domain receptor) • CD34 (CD34 molecule) • ELTD1 (Adhesion G Protein-Coupled Receptor L4)
    |
    KDR expression • ELTD1 expression
    |
    sorafenib • sunitinib